Category: Business

New STTR grant supporting GH501 study

Published on by metcure

MetCure received a $224,999 Phase I Small Business Technology Transfer (STTR) grant from the National Cancer Institute. This grant is to support the research on a potent small-molecule compound GH501 and its use in treating bone metastatic castration-resistant prostate cancer.

New STTR grant

Published on by metcure

MetCure received a $224,999 Phase I Small Business Technology Transfer (STTR) grant from the National Cancer Institute. This grant is to support the research on a potent small-molecule compound and its use in treating bone metastatic castration-resistant prostate cancer.

New STTR grant supporting BKM1644 study

Published on by metcureLeave a comment

MetCure received a $224,999 Phase I Small Business Technology Transfer (STTR) grant from the National Cancer Institute. This project is to investigate the mechanism of action and in vivo efficacy of a novel small-molecule compound (BKM1644) in treating prostate cancer.

Project Details:

Enzalutamide resistance is a major obstacle in the treatment of metastatic, castration-resistant prostate cancer (mCRPC). Recently we developed a small-molecule lead compound BKM1644 and demonstrated its potent activity against bone metastatic prostate cancer cells. In this Phase I STTR application, we hypothesize that BKM1644 is a novel targeted therapy to overcome enzalutamide resistance and effectively target bone metastasis. Two Aims are proposed: Aim 1 will evaluate the in vivo pharmacokinetics, distribution and efficacy of BKM1644 in targeting enzalutamide-resistant, bone metastatic prostate cancer in animal models. Aim 2 will determine the mechanism of action of BKM1644 in mCRPC cells. The project has immediate therapeutic potential in treating a lethal disease.

Advertisement

New STTR grant

Published on by metcure

MetCure received a $224,999 Phase I Small Business Technology Transfer (STTR) grant from the National Cancer Institute. This project is to investigate the mechanism of action and in vivo efficacy of a novel small-molecule compound in treating prostate cancer.